000963.CS
Huadong Medicine's 2026 interim net profit reaches 1.861 billion yuan
Huadong Medicine released its 2026 interim report, showing total operating revenue of 22.067 billion yuan, net profit attributable to the parent company of 1.861 billion yuan, and net cash inflow from operating activities of 2.499 billion yuan. The company's latest asset-liability ratio is 35.51 percent, ranking 66th among comparable companies that have disclosed data, up 0.88 percentage points from the previous quarter. Gross margin is 32.80 percent, ranking 88th, down 1.14 percentage points from the previous quarter and down 1.10 percentage points from the same period last year. Latest return on equity is 7.31 percent, down 0.33 percentage points from the same period last year. Diluted earnings per share is 1.06 yuan. Total asset turnover is 0.56 times, down 1.17 percent from the same period last year; inventory turnover is 2.81 times, down 3.95 percent from the same period last year. The company has 100,200 shareholders, and the top ten shareholders hold 1.177 billion shares, accounting for 67.12 percent of total share capital.
Jiemian·7hRead more ▾
Huadong Medicine's net profit for the first half of 2026 rises 2.53% year on year
Huadong Medicine released its semi-annual report for 2026, achieving operating revenue of 22.067 billion yuan, up 1.81% year on year; net profit attributable to shareholders of the listed company was 1.861 billion yuan, up 2.53% year on year. The company plans to distribute a cash dividend of 3.5 yuan per 10 shares, tax included. According to the financial report, the company's net profit for the second quarter was 859 million yuan, compared with 1.002 billion yuan in the first quarter, a quarter-on-quarter decline of 14%.
CLS·1dRead more ▾
Biotech & Genomic Medicine▲
Huadong Medicine's Innovative Drug Receives FDA Fast Track Designation
Huadong Medicine announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. has received Fast Track designation from the U.S. FDA for its self-developed injectable HDM2005, intended for the treatment of relapsed or refractory mantle cell lymphoma. This drug is the first ROR1-targeting antibody-drug conjugate in development in China to receive this designation, and clinical development is currently underway across multiple indications for malignant tumors.
CLS·1dRead more ▾
Huadong Medicine's wholly-owned subsidiary obtains registration certificate for China's first injectable product for infraorbital hollows
Sinclair Aesthetics (Hangzhou) Medical Technology Co., Ltd., a wholly-owned subsidiary of Huadong Medicine, has obtained a medical device registration certificate issued by the National Medical Products Administration. Its agent-declared Class III medical device, MaiLi Precise, a cross-linked sodium hyaluronate gel for injection containing lidocaine, has been approved for marketing, becoming China's first injectable product for treating infraorbital hollows. The product is indicated for subcutaneous and supraperiosteal injection in the infraorbital region to correct moderate to severe infraorbital hollows. The company stated that this approval will not have a significant impact on its current financial position and operating results, but will have a certain positive effect on future performance improvement.
每日经济新闻·2dRead more ▾
000963.CS▲
Talkweb Information System First-Half Net Profit Falls 12.16% Year-on-Year
Talkweb Information System released its 2026 semi-annual report, achieving operating revenue of 1.312 billion yuan, up 0.39% year-on-year, with net profit attributable to shareholders of the listed company at 69.222 million yuan, down 12.16% year-on-year. The company plans to distribute a cash dividend of 0.25 yuan for every 10 shares to all shareholders. As of the end of the reporting period, the company had over 30 products certified through OpenHarmony compatibility assessment, with related products in the market expansion and application stage. In other news, WuXi AppTec announced that a U.S. court has granted its preliminary injunction motion, shielding the company from immediate adverse impact while it challenges the U.S. Department of Defense's 1260H designation in judicial proceedings. Gaozheng Explosives' controlling shareholder is set to change to Tibet Geology and Mineral Resources Group. Ningxia Building Materials plans to repurchase shares worth 100 million to 200 million yuan for cancellation. Wuhan P&S Information Technology saw semi-annual net profit surge 209.5% year-on-year. Galaxy Microelectronics' semi-annual net profit rose 77.28% year-on-year. Hongte Technology plans to raise no more than 650 million yuan through a rights issue for its Thailand base and other projects. Tuoxin Pharmaceutical plans to raise no more than 228 million yuan through a private placement of shares. Biolight has terminated the planned change of control, and its shares and convertible bonds will resume trading on August 10. Huadong Medicine's wholly-owned subsidiary obtained EU MDR CE certification for its medical aesthetics product. Jumpcan Pharmaceutical's subsidiary obtained drug registration certificates for pediatric laxative granules and mesalazine sustained-release granules. Chinese Health's wholly-owned subsidiary had its drug registration application for ferrous succinate tablets accepted.
CLS·17dRead more ▾
Huadong Medicine Subsidiary KIO015 Receives EU MDR CE Certification
Huadong Medicine's wholly-owned subsidiary Sinclair Pharma Limited has obtained EU MDR CE certification for its injectable carboxymethyl chitosan solution KIO015, gaining market access qualification in the European Union. This is the world's first and currently the only innovative non-animal-derived chitosan medical aesthetic injectable product, branded as Kytogen® Defend, indicated for intradermal injection, superficial filling, skin quality improvement, and skin hydration. The product uses a new patented technology, with the core ingredient being KiOmedine® CM-chitosan, which has strong water absorption capacity as well as antibacterial and antioxidant properties. The company completed subject enrollment for its clinical trial in China in January 2026, expects to complete the clinical trial by the end of 2026, and plans to submit a marketing application in early 2027. Although the product has not yet obtained a domestic medical device registration certificate and has not generated actual sales revenue, the certification it has received indicates compliance with relevant EU market requirements and possession of sales qualifications, which is expected to enhance the company's performance in the future.
财中社·17dRead more ▾
000963.CS▼
Nearly 40 A-share pharma firms disclose results after 12th national procurement list published
After the proposed results of the 12th national centralized drug procurement were announced, nearly 40 A-share listed pharmaceutical companies had disclosed bid-related announcements as of the evening of August 3, with market attention continuing to heat up. This round of procurement showed clear divergence. Barefoot players like Kelun Pharmaceutical and Huahai Pharmaceutical broke through with newly approved varieties. Kelun Pharmaceutical had 14 product specifications proposed for selection, with 9 varieties having no sales revenue in 2025. Huahai Pharmaceutical had 4 proposed winning products, 3 of which were newly approved in the second quarter of 2026. Meanwhile, Huadong Medicine unexpectedly lost the bid for its core product indobufen tablets. The 4 products it failed to win had combined sales revenue of about 4.634 billion yuan in 2025, accounting for 10.62 percent of the company's total revenue, far exceeding the 2.076 billion yuan from winning products. Its market share in public hospitals faces reshaping. Companies generally view winning national procurement bids as an opportunity to quickly open the domestic sales market, but the decline in hospital share for lost varieties has raised market concerns about the short- to medium-term performance of related firms.
CLS·23dRead more ▾
Huadong Medicine's Three Products Tentatively Selected in the 12th Round of National Drug Procurement
Huadong Medicine announced that the company and its wholly-owned subsidiary participated in the 12th round of national centralized drug procurement. Cyclosporine soft capsules, tacrolimus capsules, and mesalazine enteric-coated tablets were tentatively selected. In 2025, the combined sales revenue of these products was approximately 2.076 billion yuan, accounting for 4.76% of total revenue. Four other products, including isavuconazole injection, were not selected. Their combined sales revenue in 2025 was approximately 4.634 billion yuan, accounting for 10.62% of total revenue, and their hospital market share is expected to decline. The company has formulated operational contingency plans to cope with procurement pressure.
CLS·25dRead more ▾
000963.CS▲
Huadong Medicine Chairman Proposes Mid-2026 Dividend of 3.5 Yuan per 10 Shares
Huadong Medicine Chairman Lyu Liang has proposed a mid-2026 dividend plan, suggesting a cash payout of 3.5 yuan per 10 shares, tax included, to all shareholders. The plan does not include bonus shares or conversion of capital reserve into share capital. Based on the company's current total share capital of 1.754 billion shares, the total dividend is estimated at 614 million yuan. In the first quarter of 2026, Huadong Medicine reported revenue of 11.183 billion yuan and net profit attributable to the parent company of 1.002 billion yuan.
财中社·38dRead more ▾